Table 7.
This table presents a comprehensive overview of various carrier systems, including nanoparticles and nanofibres, along with their respective active compounds. The table highlights key findings such as size, entrapment efficiency, and notable observations from studies, emphasising the potential of these carrier systems for effective drug delivery in cancer therapy and other pharmaceutical applications.
| S. No. | Carrier System | Active Compound | Size | Entrapment Efficiency | Key Findings | References |
|---|---|---|---|---|---|---|
| 1. | Nanoparticles | Docetaxel | 250.3 ± 1.7 nm | 85% | The NP components were non-toxic and safe to human cells. The prepared nanoparticles may be used as effective carriers for chemotherapeutic agents targeting carcinogenetic tissues. | [187] |
| 2. | Nanoparticles | Isolongifolene | 200–250 nm | 79.05 ± 4.60% | Isolongifolene-loaded chitosan nanoparticles were shown to be plasma-compatible and to have a consistent release pattern. As a result, chitosan-loaded nanoparticles might be used as an effective adjuvant in cancer therapy to address multi-drug resistance in solid tumours. | [188] |
| 3. | Nanoparticles | Methotrexate | 73.2 ± 4.9 nm | - | Methotrexate-loaded nanoparticles inhibited the viability of breast cancer cells when exposed to low doses. The tiny size of this efficient cytotoxic nanoparticle delivery method makes it a promising technique for use in breast cancer. | [189] |
| 4. | Nanofibre | Cisplatin | 200–350 nm | - | The prepared nanofibres are biocompatible and effective in cancer treatment. | [190] |
| 5. | Nanoparticles | Docetaxel and curcumin | 100–150 nm | 7.82% and 6.48 | The prepared nanoparticle loaded with curcumin and docetaxel can ameliorate the immunosuppressive microenvironment to promote the inhibition of tumour growth. | [191] |
| 6. | Nanoparticles | Quercetin | 291.1 ± 9.1 | 11.17 ± 1.12% | The prepared nanoparticles decrease tumour growth and provide a prospective strategy for the treatment of paclitaxel-resistant lung cancer. | [192] |
| 7. | Nanoparticles | Doxorubicin | 27.31 ± 0.78 nm | 74.40 ± 1.60% | At pH 5.0, the drug was promptly and totally liberated from the nanoparticles. The anti-HER2 conjugated OCP copolymer nanoparticles had the lowest IC50 in vitro, indicating a boost in the therapeutic effectiveness of DOX to treat human breast cancer. | [193] |
| 8. | Hydrogel nanocomposite | Curcumin | 30 nm | 62% | The proposed nanostructure is a promising vehicle with the ability to improve curcumin loading and enable prolonged curcumin release while causing considerable cytotoxicity in MCF-7 cells. | [194] |
| 9. | Hybrid nanogel containing gold nanoparticles | Doxorubicin | 119.3 nm | 56% | The present research demonstrated that the designed enzyme-responsive nanogel could potentially target various solid tumours both actively and passively. | [195] |
| 10. | Nanoparticles | Doxorubicin and Cisplatin | 160 nm | 21.4% for DOX and 81.71 for CP | In human breast cancer MCF-7 cells, DOX plus cisplatin had a synergistic cell-killing impact. The findings clearly show that the innovative nanoplatform holds great promise for synergistic combination treatment of breast cancer. | [196] |
OCP—O-succinyl chitosan graft Pluronic® F127; DOX—doxorubicin; CP—cisplatin.